MS Brain Health newsletter – June 2018


Dear supporters 
Over the past month, we have presented MS Brain Health research at major conferences in Europe, the USA and Australia and learned more about the experiences of people living with MS in the USA. It has been great to meet some of you in person at these events, and we are pleased to welcome many new supporters!

Consensus standards presented at EAN 2018 
International consensus standards for the timing of key stages in MS care were presented in our focused workshop, Brain Health in MS: a catalyst for a new approach to management, at EAN 2018 in Lisbon this month. Over 150 attendees joined this interactive workshop and gave their responses to the new quality standards.
Professor Gavin Giovannoni, Dr Gisela Kobelt and Professor Jeremy Hobart gave presentations and participated in a lively Q&A session. “The standards should not be used as a means to criticize MS teams, but instead provide an opportunity for every MS clinic to strive for the highest level of care,” stressed Professor Hobart.
Read more
Latest MS Brain Health presentations available to download
Professional organizations in Australasia endorse the policy report
MS Nurses Australasia and the MS Neurology subspecialty group of the Australian and New Zealand Association of Neurologists have become the latest professional groups to officially endorse the policy report, Brain health: time matters in multiple sclerosis. We’re delighted that these groups have joined our other 46 endorsers.
Revisions to criteria used in the diagnosis of MS
Motivated by recent technological advances and new data on the diagnosis of MS, experts have refined the 2010 McDonald criteria – the widely used diagnostic criteria for MS. The experts hope that the updated criteria will facilitate early and accurate diagnosis of MS.
Read more
New! Dutch translations of short guides
We are delighted to announce that our guide for people with MS and nursing resource are now available in Dutch. Follow the links above, click ‘Download’ and select your language.

Please do share these resources with your Dutch-speaking colleagues and friends.

You can follow us on Twitter @MSBrainHealth to keep up with the latest news. Thank you for your continuing support!
Gavin Giovannoni, MD

Professor of Neurology and Chair of the MS Brain Health Steering Committee

On behalf of the MS Brain Health Steering Committee: Gavin Giovannoni, Peer Baneke, Helmut Butzkueven, Jodi Haartsen, Jeremy Hobart, Gisela Kobelt, Christoph Thalheim, Tony Traboulsee, Tim Vollmer and Tjalf Ziemssen

If this newsletter has been forwarded to you,
click here to subscribe to future issues.

Follow @MSBrainHealth on Twitter

Having trouble viewing the content of this post? View this post in your browser
MS Brain Health activities and supporting materials are funded by grants from Actelion, Celgene and Sanofi Genzyme and by educational grants from Biogen, F. Hoffmann-La Roche and Merck KGaA, all of whom have no influence on the content.

Editorial and administrative support for the MS Brain Health initiative is provided by Oxford Health Policy Forum, a not-for-profit community interest company registered in England and Wales (registration number: 10475240).

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.


  • ….And Roche….

    Patients' Choice
    Rare Disease
    Overarching Theme

    Day 1 (16.06.2018)
    Career Development Session 1
    08:30 – 10:00 Room Oslo

    Etiological investigation of disease: case-control studies
    Case-based Workshop 1
    08:30 – 10:00 Room CbW

    EAN/EAPC: End-of-life care for neurological patients
    Focused Workshop 1
    08:30 – 10:00 Auditorium III

    Brain health in multiple sclerosis: a catalyst for a new approach to management
    Focused Workshop 2
    08:30 – 10:00 Auditorium V

    Biomarkers of neuromuscular disorders
    Focused Workshop 3
    08:30 – 10:00 Room Lisbon

    The importance of brain network reorganisation in old age and for successful rehabilitation after stroke
    Focused Workshop 4
    08:30 – 10:00 Room Copenhagen

    Ability to drive in neurological disorders
    Focused Workshop 5
    08:30 – 10:00 Room Berlin

    Overarching theme: Familial amyloid polyneuropathy: phenotype, genetics, treatment
    Interactive Session 1
    08:30 – 10:00 Auditorium VI

    EAN/ILAE-CEA: Classification of the epilepsies: Old wine in new skins?
    Special Session 12
    08:30 – 10:00 Room Amsterdam

    25 Years of European Journal of Neurology – History, future and how to prepare your paper for publication
    3-Days Satellite Session 1
    10:00 – 10:30 Room 0.01

    CELGENE – The importance of real world evidence generation in Multiple Sclerosis
    Forum Programmes 1
    10:15 – 10:30 Scientific Theatre

    MERCK TALK – Multiple Sclerosis

    Selective Immune Reconstitution Therapy in the Multiple Sclerosis treatment paradigm
    Gavin Giovannoni, London, United Kingdom

    Symposium 1
    10:30 – 12:30 Auditorium I

    EAN/MDS-ES: Tauopathies: pathophysiology, clinical features and experimental therapies
    Symposium 2
    10:30 – 12:30 Auditorium VI

    Diagnosing genetic epilepsies
    Symposium 3
    10:30 – 12:30 Auditorium V

    EAN/ESO: Cerebral small vessel disease – recent advances and clinical implications
    Symposium 4
    10:30 – 12:30 Auditorium VIII

    EAN/EAPC: Palliative care and neurology
    Symposium 9
    10:30 – 12:30 Room Berlin

    EAN/ECTRIMS: Therapeutic challenges in progressive multiple sclerosis
    Scientific Theatre 1
    10:30 – 11:00

    European Pain Federation
    Scientific Theatre 2
    11:30 – 12:00

    EAN grants and other possibilities
    Scientific Theatre 3
    12:30 – 13:00

    eBook on neurological examination
    Satellite Symposium 02
    13:00 – 14:30 Auditorium VI

    ROCHE – Redefining the management of relapsing Multiple Sclerosis & primary progressive Multiple Sclerosis

    Gavin Giovannoni, London, United Kingdom

    Welcome and introduction
    Gavin Giovannoni, London, United Kingdom

    Suppressing disease activity and progression in relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
    Gavin Giovannoni, London, United Kingdom

    Ocrelizumab safety across relapsing Multiple Sclerosis and primary progressive Multiple Sclerosis
    Ralf Gold, Bochum, Germany

    Incorporating Ocrelizumab into clinical practice
    Aaron Boster, Ohio, United States

    Questions & Answers
    All faculty, ,

    Gavin Giovannoni, London, United Kingdom

By Prof G



Recent Posts

Recent Comments